New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml;   - concentrate for injection - 200 mg/40 ml - active: ipilimumab 5 mg/ml   excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml;   - concentrate for injection - 50 mg/10 ml - active: ipilimumab 5 mg/ml   excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - nivolumab 10 mg/ml;  ;  ;   - concentrate for infusion - 100 mg/10ml - active: nivolumab 10 mg/ml       excipient: hydrochloric acid mannitol pentetic acid polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - opdivo, as monotherapy is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, in combination with yervoy (ipilimumab) is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, as monotherapy, is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - nivolumab 10 mg/ml;  ;  ;   - concentrate for infusion - 40 mg/4ml - active: nivolumab 10 mg/ml       excipient: hydrochloric acid mannitol pentetic acid polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - opdivo, as monotherapy is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, in combination with yervoy (ipilimumab) is indicated for the treatment of patients with unresectable or metastatic melanoma. opdivo, as monotherapy, is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - daclatasvir dihydrochloride 33mg equivalent to daclatasvir 30mg - tablet - 30 mg - active: daclatasvir dihydrochloride 33mg equivalent to daclatasvir 30mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry green - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults with compensated liver disease (including cirrhosis).

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - daclatasvir dihydrochloride 66mg equivalent to daclatasvir 60mg - tablet - 60 mg - active: daclatasvir dihydrochloride 66mg equivalent to daclatasvir 60mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry green - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults with compensated liver disease (including cirrhosis).

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 125mg;   - capsule - 125 mg - active: didanosine 125mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint tan sw-8010 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 200mg;   - capsule - 200 mg - active: didanosine 200mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint green sb-4020 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 250mg;   - capsule - 250 mg - active: didanosine 250mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint blue sb-6018 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 400mg;   - capsule - 400 mg - active: didanosine 400mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer opacode red s-1-15094 opacode red s-1-15095 purified talc sodium starch glycolate titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.